Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and quality of life with maintenance olaparib plus bevacizumab in older patients with ovarian cancer: subgroup analysis of PAOLA‑1/ENGOT-ov25.
Montégut C, Falandry C, Cinieri S, Cropet C, Montane L, Rousseau F, Joly F, Moubarak M, Mosconi AM, Guerra-Alía EM, Schauer C, Fujiwara H, Vergote I, Parma G, Lindahl G, Anota A, Canzler U, Marmé F, Pujade-Lauraine E, Ray-Coquard I, Sabatier R. Montégut C, et al. Among authors: mosconi am. Oncologist. 2024 Dec 14:oyae322. doi: 10.1093/oncolo/oyae322. Online ahead of print. Oncologist. 2024. PMID: 39673779 Free article.
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.
Harter P, Marth C, Mouret-Reynier MA, Cropet C, Lorusso D, Guerra-Alía EM, Matsumoto T, Vergote I, Colombo N, Mäenpää J, Lebreton C, de Gregorio N, Mosconi AM, Rubio-Pérez MJ, Bourgeois H, Fasching PA, Cecere SC, Hardy-Bessard AC, Denschlag D, de Percin S, Hanker L, Favier L, Bauerschlag D, Desauw C, Hillemanns P, Largillier R, Sehouli J, Grenier J, Pujade-Lauraine E, Ray-Coquard I; PAOLA-1/ENGOT-ov25 investigators. Harter P, et al. Among authors: mosconi am. Ann Oncol. 2024 Nov 9:S0923-7534(24)04907-X. doi: 10.1016/j.annonc.2024.10.828. Online ahead of print. Ann Oncol. 2024. PMID: 39528049 Free article.
Can Morphology and Immune Infiltration Predict the Homologous Recombination Deficiency Status in Newly Diagnosed High-Grade Serous Ovarian Carcinoma?
Kime A, Bataillon G, Treilleux I, Callens C, Selle F, Heitz F, Cinieri S, González-Martin A, Schauer C, Lindahl G, Parma G, Vergote I, Matsumoto T, Blonz C, Canzler U, Mosconi AM, Guerra Alía EM, Pujade-Lauraine E, Genestie C, Ray-Coquard I, Just PA. Kime A, et al. Among authors: mosconi am. Arch Pathol Lab Med. 2024 Dec 9. doi: 10.5858/arpa.2024-0081-OA. Online ahead of print. Arch Pathol Lab Med. 2024. PMID: 39648143 Free article.
Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial.
Lorusso D, Raspagliesi F, Ronzulli D, Valabrega G, Colombo N, Pisano C, Cassani C, Tognon G, Tamberi S, Mangili G, Mammoliti S, De Giorgi U, Greco F, Mosconi AM, Breda E, Artioli G, Andreetta C, Casanova C, Ceccherini R, Frassoldati A, Salutari V, Giolitto S, Scambia G. Lorusso D, et al. Among authors: mosconi am. J Clin Oncol. 2024 May 1;42(13):1488-1498. doi: 10.1200/JCO.23.01225. Epub 2024 Feb 5. J Clin Oncol. 2024. PMID: 38315944 Clinical Trial.
Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group.
Musacchio L, Palluzzi E, Di Napoli M, Lauria R, Ferrandina G, Angioli R, Bergamini A, Corrado G, Perniola G, Cassani C, Savarese A, Gori S, Greco F, De Angelis C, Zafarana E, Giannarelli D, Cinieri S, Mosconi AM, Raspagliesi F, Pignata S, Scambia G, Lorusso D. Musacchio L, et al. Among authors: mosconi am. Gynecol Oncol. 2024 May;184:24-30. doi: 10.1016/j.ygyno.2024.01.022. Epub 2024 Jan 25. Gynecol Oncol. 2024. PMID: 38277918
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
Balmaña J, Fasching PA, Couch FJ, Delaloge S, Labidi-Galy I, O'Shaughnessy J, Park YH, Eisen AF, You B, Bourgeois H, Gonçalves A, Kemp Z, Swampillai A, Jankowski T, Sohn JH, Poddubskaya E, Mukhametshina G, Aksoy S, Timcheva CV, Park-Simon TW, Antón-Torres A, John E, Baria K, Gibson I, Gelmon KA; LUCY investigators. Balmaña J, et al. Breast Cancer Res Treat. 2024 Apr;204(2):237-248. doi: 10.1007/s10549-023-07165-x. Epub 2023 Dec 19. Breast Cancer Res Treat. 2024. PMID: 38112922 Free PMC article. Clinical Trial.
Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer.
Leman R, Muller E, Legros A, Goardon N, Chentli I, Atkinson A, Tranchant A, Castera L, Krieger S, Ricou A, Boulouard F, Joly F, Boucly R, Dumont A, Basset N, Coulet F, Chevalier LM, Rouleau E, Leitner K, González-Martin A, Gargiulo P, Lück HJ, Genestie C; PAOLA-1 investigators; Ray-Coquard I, Pujade-Lauraine E, Vaur D. Leman R, et al. Clin Cancer Res. 2023 Nov 1;29(21):4419-4429. doi: 10.1158/1078-0432.CCR-23-0898. Clin Cancer Res. 2023. PMID: 37756555 Free PMC article.
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.
Ray-Coquard I, Leary A, Pignata S, Cropet C, González-Martín A, Marth C, Nagao S, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alia EM, Bogner G, Yoshida H, Lefeuvre-Plesse C, Buderath P, Mosconi AM, Lortholary A, Burges A, Medioni J, El-Balat A, Rodrigues M, Park-Simon TW, Dubot C, Denschlag D, You B, Pujade-Lauraine E, Harter P; PAOLA-1/ENGOT-ov25 investigators. Ray-Coquard I, et al. Among authors: mosconi am. Ann Oncol. 2023 Aug;34(8):681-692. doi: 10.1016/j.annonc.2023.05.005. Epub 2023 May 19. Ann Oncol. 2023. PMID: 37211045 Free article. Clinical Trial.
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Pignata S, Scambia G, Schettino C, Arenare L, Pisano C, Lombardi D, De Giorgi U, Andreetta C, Cinieri S, De Angelis C, Priolo D, Casanova C, Rosati M, Greco F, Zafarana E, Schiavetto I, Mammoliti S, Cecere SC, Salutari V, Scalone S, Farolfi A, Di Napoli M, Lorusso D, Gargiulo P, Califano D, Russo D, Spina A, De Cecio R, Chiodini P, Perrone F; MITO investigators. Pignata S, et al. Lancet Oncol. 2023 Mar;24(3):286-296. doi: 10.1016/S1470-2045(23)00016-5. Epub 2023 Feb 14. Lancet Oncol. 2023. PMID: 37052965 Clinical Trial.
Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.
Labidi-Galy SI, Rodrigues M, Sandoval JL, Kurtz JE, Heitz F, Mosconi AM, Romero I, Denison U, Nagao S, Vergote I, Parma G, Nøttrup TJ, Rouleau E, Garnier G, El-Balat A, Zamagni C, Martín-Lorente C, Pujade-Lauraine E, Fiévet A, Ray-Coquard IL. Labidi-Galy SI, et al. Among authors: mosconi am. Ann Oncol. 2023 Feb;34(2):152-162. doi: 10.1016/j.annonc.2022.11.003. Epub 2022 Nov 28. Ann Oncol. 2023. PMID: 36564284 Free article.
48 results